{
    "id": 4933,
    "fullName": "VEGFA amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "VEGFA amp indicates an increased number of copies of the Vegfa gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7422,
        "geneSymbol": "VEGFA",
        "terms": [
            "VEGFA",
            "MVCD1",
            "VEGF",
            "VPF"
        ]
    },
    "variant": "amp",
    "createDate": "04/16/2015",
    "updateDate": "08/29/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9849,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse model of hepatocellular carcinoma harboring VEGFA amplification demonstrated a reduction in Hgf levels and decreased cell proliferation when treated with Nexavar (sorafenib) (PMID: 24687604).",
            "molecularProfile": {
                "id": 4727,
                "profileName": "VEGFA amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7686,
                    "pubMedId": 24687604,
                    "title": "Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24687604"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9848,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Nexavar (sorafenib) treatment in hepatocellular carcinoma patients harboring VEGFA amplification resulted in an improved survival compared to Nexavar (sorafenib) treated patients not harboring VEGFA amplification (PMID: 24687604).",
            "molecularProfile": {
                "id": 4727,
                "profileName": "VEGFA amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7686,
                    "pubMedId": 24687604,
                    "title": "Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24687604"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21296,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft model of osteosarcoma with VEGFA amplification was sensitive to treatment with Nexavar (sorafenib), demonstrating decreased tumor volume and cell proliferation and a tumor growth inhibition of 79% (PMID: 30266815)",
            "molecularProfile": {
                "id": 4727,
                "profileName": "VEGFA amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4727,
            "profileName": "VEGFA amp",
            "profileTreatmentApproaches": [
                {
                    "id": 3503,
                    "name": "VEGF Antibody",
                    "profileName": "VEGFA amp"
                },
                {
                    "id": 3502,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "VEGFA amp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}